07:00 , Apr 14, 2014 |  BC Week In Review  |  Clinical News

Ampligen rintatolimod: Additional Phase III data

A post hoc analysis of the double-blind, U.S. Phase III AMP-516 trial in 234 patients showed that 39% of patients receiving twice-weekly Ampligen achieved a >=25% improvement in ETT duration from baseline to week 40,...
08:00 , Jan 6, 2014 |  BC Week In Review  |  Clinical News

Ampligen rintatolimod: Phase II started

Last month, Hemispherx said it began the Phase II portion of a double-blind, placebo-controlled, U.S. Phase I/II trial comparing nasal adjuvant Ampligen plus FluMist vs. FluMist alone in 72 healthy volunteers. The Phase II portion...
07:00 , May 7, 2012 |  BC Week In Review  |  Clinical News

Ampligen rintatolimod: Phase I/II started

Hemispherx began a double-blind, placebo-controlled, U.S. Phase I/II to compare nasal adjuvant Ampligen plus Flumist vs. Flumist alone in 72 healthy volunteers. MedImmune LLC , a subsidiary of AstraZeneca plc (LSE:AZN; NYSE:AZN, London, U.K.), markets...
07:00 , Aug 29, 2011 |  BC Week In Review  |  Clinical News

Ampligen rintatolimod: Phase I/II started

Hemispherx said investigators began an open-label, U.S. Phase I/II trial to evaluate 4, 20, 79 and 495 µg intradermal Ampligen plus the university's vaccine consisting of synthetic peptide derived from epidermal growth factor receptor 2...
07:00 , Jun 27, 2011 |  BC Week In Review  |  Clinical News

Ampligen rintatolimod: Phase I/II started

Investigators at the University of Pennsylvania School of Medicine began a U.S. Phase I/II trial to evaluate its vaccine comprised of autologous oxidized tumor cell lystate (OC-L) in combination with 200 mg IV Ampligen as...
08:00 , Dec 6, 2010 |  BC Week In Review  |  Clinical News

Ampligen rintatolimod: Additional Phase III data

Additional data from the 40-week, double-blind, U.S. Phase III AMP-516 trial in 234 patients showed that patients treated with placebo had significant prolongation of QT intervals compared to patients treated with twice-weekly Ampligen (p=0.049). Hemispherx...